Archive · 17 Sep 2026
India Restricts Autism Stem Cell Therapy To Approved Clinical Trials
The government has warned clinics not to sell stem cell treatment as a regular cure for autism.
Doctors may use it for autism only in properly approved clinical studies.
It cannot be advertised or provided as an ordinary commercial service.
Regular stem cell care is allowed only for conditions on an approved list.
The rule follows directions from the Supreme Court.
The National Medical Commission has also repeated the warning.
Doctors who break the rules may face disciplinary action.
Clinics could also lose their registration or face penalties.
The Union Health Ministry said stem cell therapy for autism may only be used in duly approved clinical trials.
The ministry said stem cell therapy can be routine care only for conditions included in approved indications.
Its advisory cites the National Guidelines for Stem Cell Research, 2017, issued by the ICMR and DBT.
Authorities were told to share the Supreme Court’s directions with regulators and clinical establishments.
Violations may lead to professional-misconduct action, registration cancellation, penalties, or disciplinary proceedings.
- Who
- The Union Health Ministry, the National Medical Commission, state and Union Territory authorities, and clinical establishments are involved.
- What
- Stem cell therapy for autism has been restricted to duly approved clinical trials and may not be offered as routine or commercial treatment.
- When
- The Health Ministry issued its advisory on September 16; the National Medical Commission issued a related advisory on September 5, and the cited Supreme Court judgment was delivered on January 30, 2026.
- Where
- The directive applies across India, including states, Union Territories, and government and private clinical establishments.
- Why
- To enforce the existing regulatory framework and prevent unproven stem cell interventions from being offered as standard or commercial care.
- Permitted autism use
- Only as part of duly approved clinical trials
- Routine-care rule
- Stem cell therapy may be standard care only for approved conditions or indications
- Relevant guidelines
- National Guidelines for Stem Cell Research, 2017
- Issuing bodies
- Indian Council of Medical Research and Department of Biotechnology
- Supreme Court judgment
- Yash Charitable Trust & Ors. v. Union of India & Ors., January 30, 2026
- Possible consequences
- Professional-misconduct action, registration cancellation, penalties, or disciplinary action
- Related regulator advisory
- The National Medical Commission issued an advisory dated September 5